俯卧位与仰卧位[18F]FDG-PET/CT在临床淋巴结阳性乳腺癌新辅助治疗前腋窝分期中的价值
本研究纳入153例临床淋巴结阳性乳腺癌患者,在MARI协议下分别进行俯卧位和仰卧位[18F]FDG-PET/CT腋窝分期。俯卧位评估导致24例(16%)患者分期上调或下调,但两名观察者仅对1例(1%)的分期改变达成一致。俯卧位观察者间一致性(86%,K=0.67)低于仰卧位(92%,K=0.80)。因此,仅仰卧位FDG-PET/CT即可满足腋窝分期需要。
要点
- 俯卧位与仰卧位FDG-PET/CT腋窝分期改变不一致,仅1%患者达成共识。
- 俯卧位观察者间一致性(K=0.67)低于仰卧位(K=0.80)。
- 仅仰卧位FDG-PET/CT即可满足临床淋巴结阳性乳腺癌腋窝分期。
核心结论
- 俯卧位较仰卧位FDG-PET/CT未产生一致的腋窝分期上调或下调,仅仰卧位扫描即可满足分期需求。
研究设计与样本
- 回顾性选取153例接受MARI协议的临床淋巴结阳性乳腺癌患者,均行俯卧位低剂量CT胸部和仰卧位全身[18F]FDG-PET/CT扫描。
主要发现
- 俯卧位图像评估中24例(16%)患者分期上调或下调。
- 一名观察者上调14例、下调3例,并报告更多腋窝淋巴结(3.6 vs. 3.2,p<0.001)。
- 另一名观察者分期改变(上调4例、下调5例)和淋巴结数目(2.8 vs. 2.8)无差异。
- 观察者仅对1例(1%)患者的分期改变达成一致。
- 无论仰卧位或俯卧位,观察者腋窝分期一致124例(81%),不一致5例(3%)。
关键数值与推荐
- 腋窝分期按FDG阳性腋窝淋巴结数目分类为cALN<4或cALN≥4。
- 注射3.5 MBq/kg [18F]FDG后1小时进行PET扫描。
临床怎么用
- 对于临床淋巴结阳性乳腺癌患者新辅助治疗前腋窝分期,可仅采用仰卧位FDG-PET/CT,无需额外俯卧位扫描。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Axillary staging before neoadjuvant systemic therapy in clinically node-positive breast cancer patients with tailored axillary treatment according to the Marking Axillary lymph nodes with radioactive iodine seeds (MARI)-protocol, a protocol developed at the Netherlands Cancer Institute, is performed with [18F] fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT). We aimed to assess the value of FDG-PET/CT in prone compared to standard supine position for axillary staging. METHODS: We selected patients with FDG-PET/CT in supine and prone position who underwent the MARI-protocol. One hour after administration of 3.5 MBq/kg, [18F]FDG-PET was performed with a low-dose prone position CT-thorax followed by a supine whole-body scan. Scans were separately reviewed by two nuclear medicine physicians and categorized by number of FDG-positive axillary lymph nodes (ALNs; cALN<4 or cALN≥4). Main outcome was axillary up- or downstaging. RESULTS: Of 153 patients included, 24 (16%) patients were up- or downstaged at evaluation of prone images: One observer upstaged 14 patients, downstaged 3 patients and reported a higher number of ALNs (3.6 vs. 3.2, p < 0.001), while staging (4 up- and 5 downstaged) and number of ALNs (2.8 vs. 2.8) did not differ for the other. Observers agreed on up- or downstaging in only 1 (1%) patient. Irrespective of supine or prone position scanning, observers agreed on axillary staging in 124 (81%) patients and disagreed in 5 (3%). Interobserver agreement was lower with prone assessments (86%, K = 0.67) than supine (92%, K = 0.80). CONCLUSIONS: Axillary staging with FDG-PET/CT in prone compared to supine position did not result in concordant up- or downstaging. Therefore, FDG-PET/CT in supine position only can be considered sufficient for axillary staging.
引用
- van Loevezijn AA, Stokkel MPM, Donswijk ML, et al. [18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy. EJNMMI Res. 2021. PMID: 34417932. doi:10.1186/s13550-021-00824-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。